Incyte (INCY)

• Market cap: $11.8B
• 1 day: 3.17%
• 5 days: -1.71%
• 1 month: 2.75%
• 3 months: -11.88%
• 6 months: -24.48%
• Year to date: -12.48%
• 1 year: 5.64%
• 5 years: -37.10%
• 10 years: -42.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,617

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

121% more first-time investments, than exits

New positions opened: 126 | Existing positions closed: 57

86% more call options, than puts

Call options by funds: $68.6M | Put options by funds: $37M

16% more repeat investments, than reductions

Existing positions increased: 238 | Existing positions reduced: 206

14% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]

10% more funds holding

Funds holding: 577 [Q3] → 635 (+58) [Q4]

6% more capital invested

Capital invested by funds: $11.9B [Q3] → $12.6B (+$687M) [Q4]

1.09% more ownership

Funds ownership: 93.56% [Q3] → 94.65% (+1.09%) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $59 3% downside
• Avg. target: $71 16% upside
• High target: $92 51% upside

6 analyst ratings

• positive: 0 0%
• neutral: 6 100%
• negative: 0 0%

Wells Fargo Derek Archila 41% 1-year accuracy 12 / 29 met price target	3% downside $59	Equal-Weight Maintained	30 Apr 2025
RBC Capital Brian Abrahams 15% 1-year accuracy 11 / 73 met price target	10% upside $67	Sector Perform Maintained	30 Apr 2025
JP Morgan Jessica Fye 49% 1-year accuracy 20 / 41 met price target	12% upside $68	Neutral Maintained	21 Apr 2025
Morgan Stanley Vikram Purohit 17% 1-year accuracy 1 / 6 met price target	7% upside $65	Equal-Weight Maintained	24 Mar 2025
Truist Securities Srikripa Devarakonda 13% 1-year accuracy 4 / 32 met price target	18% upside $72	Hold Maintained	18 Mar 2025